Sage rebounds after next-gen postpartum depression readout

Sage Therapeutics Inc. (NASDAQ:SAGE) gained $41.62 (43%) to $139.13 on Jan. 7 after it said SAGE-217 met the primary endpoint in the Phase III ROBIN trial to treat women with severe postpartum depression. The move

Read the full 355 word article

User Sign In